Abstract:
The present invention provides compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of a disease or disorder associated with the crystallization of monosodium urate monohydrate, wherein R 1 and R 2 are different and are selected from -H and -(C 1 -C 6 )alkyl; and R 3 is selected from -H and =O. The invention also provides an in vitro method for eliminating and/or preventing the formation of monosodium urate monohydrate crystals in a composition, and an i n vitro use of a compound of formula (I) for eliminating and/or preventing the formation of monosodium urate monohydrate crystals.
Abstract:
The present invention relates to the utilisation of myo-inositol hexaphosphate or pharmaceutically-acceptable salts thereof for the manufacture of a medicament destined for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. Said compound may be utilised in the manufacture of functional foods, dietetic complements, vitamin complements or nutritional complements or food complements or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts.